Respiri's (ASX:RSH) patient programs showed a "significant" reduction in hospitalizations and emergency room visits, accelerating discussions with new and existing clients, according to a Friday filing with the Australian bourse.
The programs registered a 56% decline in rehospitalizations and a 47% drop in emergency room visits.
The medical devices company is in advanced contract discussions with new potential clients as it increases revenues for existing partner Ceras' clients by 51%, to $74 from around $49 per patient per month, and increased the number of monthly reimbursed services to patients to 1.4 from around 1, the filing stated.
The company's shares jumped 5% in recent Monday trade.
Price (AUD): $0.04, Change: $+0.002, Percent Change: +5.00%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。